Copyright: ©Author(s) 2026. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution-NonCommercial (CC BY-NC 4.0) license. No commercial re-use. See permissions. Published by Baishideng Publishing Group Inc.
World J Stem Cells. Jun 26, 2026; 18(6): 118524
Published online Jun 26, 2026. doi: 10.4252/wjsc.118524
Published online Jun 26, 2026. doi: 10.4252/wjsc.118524
Mesenchymal stem cells mediate the temporal modulation of aging-related changes
Ilya D Klabukov, Anna Smirnova, Denis S Baranovskii, Department of Regenerative Medicine, National Medical Research Radiological Center, Obninsk 249036, Kaluzhskaya Oblast’, Russia
Ilya D Klabukov, Anna Smirnova, Obninsk Institute for Nuclear Power Engineering, National Research Nuclear University MEPhI, Obninsk 249033, Kaluzhskaya Oblast’, Russia
Yana Sulina, Department of Obstetrics, Gynecology and Perinatal Medicine, Sechenov First Moscow State Medical University (Sechenov University), Moscow 119435, Moskva, Russia
Denis S Baranovskii, Institute of Systems Biology and Medicine, Russian University of Medicine, Moscow 117997, Moskva, Russia
Author contributions: Klabukov ID designed and performed the research, and wrote and revised the manuscript; Smirnova A, Sulina Y, and Baranovskii DS analyzed the data.
Conflict-of-interest statement: All the authors report no relevant conflicts of interest for this article.
Corresponding author: Ilya D Klabukov, PhD, Associate Professor, Head, Department of Regenerative Medicine, National Medical Research Radiological Center, 4 Koroleva Street, Obninsk 249036, Kaluzhskaya Oblast’, Russia. ilya.klabukov@gmail.com
Received: January 5, 2026
Revised: January 20, 2026
Accepted: February 24, 2026
Published online: June 26, 2026
Processing time: 172 Days and 0.5 Hours
Revised: January 20, 2026
Accepted: February 24, 2026
Published online: June 26, 2026
Processing time: 172 Days and 0.5 Hours
Core Tip
Core Tip: Mesenchymal stem cells (MSCs) show promise in regenerative medicine, but their use in elderly patients requires careful consideration. Aging presents unique challenges, such as immunosenescence, an increased risk of cancer, cellular senescence, and vascular complications. These challenges highlight the importance of performing thorough preclinical and clinical studies to assess the safety and effectiveness of MSC therapy. Furthermore, they could lead to a reevaluation of the role of MSC subpopulations as novel, unconventional therapeutic targets.